跳至主要内容
临床试验/NCT00150436
NCT00150436已完成3 期

An Open-Label Extension Safety and Efficacy Study of Pregabalin in Patients With Postherpetic Neuralgia

Pfizer0 个研究点目标入组 276 人开始时间: 2002年2月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
276
主要终点
Safety Efficacy

研究概览

简要总结

To evaluate long-term safety and efficacy of pregabalin in patients with postherpetic neuralgia.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must have met the inclusion criteria for preceding double-blind BID study in postherpetic neuralgia
  • Must have received pregabalin/placebo under double-blind conditions for a minimum of 3 weeks.

排除标准

  • Patients cannot participate if they experienced a serious adverse event during preceding double-blind BID study which was determined to be related to the study medication.

结局指标

主要结局

Safety Efficacy

次要结局

未报告次要终点

研究者

发起方
Pfizer
申办方类型
Industry

相似试验

To Evaluate Long-Term Safety and Efficacy of... | 临床试验